%20LIMITED%2020-Aug-2007_files/image002.jpg){kind=small}
MIRA
INFORM REPORT
|
Report Date : |
20.08.2007 |
IDENTIFICATION DETAILS
|
Name : |
PHARMEDIC LABORATORIES (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
16-KM, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
2006 |
|
|
|
|
Date of Incorporation : |
1993 |
|
|
|
|
Com. Reg. No.: |
0031742 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
COMPANY NAME
PHARMEDIC LABORATORIES (PRIVATE) LIMITED
Address
Registered Address & Factory
16-KM,
Tel 92 (42) 7510497, 7510498, 7513404, 7513403
Fax 92 (42) 7511396
Email pharmediclab@yahoo.com
Short Description Of
Business
Nature of Business Manufacture & Marketing of Pharmaceutical Products
Year Established 1993
Registration # 0031742
Branches
In
Auditors
Ahmad Mushir & Co.
(Chartered Accountants)
16,
Legal Status
Subject Company was established as a Private Limited Company in 1993
Authorised Capital
Rs. 40,000,000/- divided into 400,000 shares of Rs. 100/- each
Issued & Paid up
Capital
Rs. 22,116,300/- divided into 221,163 shares of Rs. 100/- each
Details of Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Iftikhar Ahmed Sheikh Mrs. Sajida Iftikhar Miss Sabah Imran Miss Razia Khatoon |
Pakistani Pakistani Pakistani Pakistani |
House No.113-A, House No.113-A, House No.113-A, House No.113-A, |
Business Business Business Business |
Chief Executive Director Director Director |
Shareholders
Names
Mr. Iftikhar Ahmed Sheikh
Mrs. Sajida Iftikhar
Miss Sabah Imran
Miss Razia Khatoon
Associates
Subsidiary
None
Associated Companies
Do
Products
Manufacture & marketing of different pharmaceutical class like
Anti Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine, Narcotic Analgesic,
Non Steroidal Respiratory Anti Inflamatory, Quinolones, Vitamins, henothiazine, Hypolipidaemics, Muscle
Relaxant, Amoebicide, Calcium-Antagonist, Cardio Selective Beta Blocker with
their brand names of ALCASAR, AMIFOS, AMOTRIP, ARTEX, ATELOR, BENDA, BIOFER,
CALCIDRON, CARBIZOLE, CARTILAN, CEFOTRIM, CEFUCEF, CEPLATIN, CHLOROMAX, CIPLOX,
CISTAZINE, CLOMINOL, CYCLIDINE, CYCLOMIDE, CYTOCIN, D-BLASTIN, D-RUBICIN,
DARBAZINE, DARVIN, DIABIN, DORFENE, E-RUBICIN, EPILANTIN, FLUPHAN, FLUTEN,
FOLACIN, FOSFORIN, GLIFEN, GLIPASE, HALODOL, HEPAFERON, HISTALEX, HYDROQUINE,
HYDROUREA, IFOSFAMIN, ISOCARDIN, KANALAR, LANSOR, LARSEN, LEUCOCIN-15,
LEUCOCIN-50, LOMEDIN, LOSOMIDE, NAPROX, NEOLYTE-ORS, NILPAR, ORALEXIN,
PACLITAX, PHARMAZORINE, POLYCEF, PROCARBIZOL, PROCEF, PROCYCLIDINE, PROVERM,
REGELAN, SENSIVAL, TAMOX, TAXIRON, THERASEPT, THYROX, TOPOSIDE, TRADOL
Number of Employees
180
Annual Production
Volume
The capacity and production of the company’s plant is indeterminable as it is multi-product and involves varying processes of manufacturing.
Annual Sales Volume
Year In Pak Rupees
2006 200,000,000/- (Estimated)
Trade Suppliers
(Foreign)
(1) JRS PHARMA GMBH & CO,
(2) SHANGHAI SIPI PHARMACEUTICAL CO. LTD,
(3) HEBEI SHENGXUE DACHENG PHARMACEUTICAL CO. LTD,
Distributors
More than 70 Distributors in all over
Exporting Countries
Mainly to
Bankers
Faysal Bank Limited,
Bank Alhabib Limited,
Memberships
Foreign Exchange
Rates
Currency Unit Pakistani Rupee
US Dollar 1 Rs. 60.75
Euro 1 Rs. 81.65
Comments
Subject Company was established in 1993 and is engaged in manufacturing & marketing of Pharmaceutical Products. Directors are reported as resourceful and experienced businessmen. Trade relations are reported as fair. The Company can be considered for normal business dealings at usual trade terms and conditions.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)